GSK Contests $5.2 Bil. Tax Bill After IRS Decision On Zantac Transfer Pricing
Executive Summary
GlaxoSmithKline and the Internal Revenue Service are headed to court over the IRS' conclusion that the company owes $5.2 bil. for unpaid taxes, penalty charges and interest
You may also be interested in...
U.S. Drug Firms Under IRS Scrutiny For Offshore Income Shifting
U.S.-based drug companies inappropriately reported that foreign profits accounted for 66% of their worldwide profits in 2003-2005, 23% more than the amount calculated by Tax Analysts, according to a publication by the non-profit group
U.S. Drug Firms Under IRS Scrutiny For Offshore Income Shifting
U.S.-based drug companies inappropriately reported that foreign profits accounted for 66% of their worldwide profits in 2003-2005, 23% more than the amount calculated by Tax Analysts, according to a publication by the non-profit group
GSK tax dispute
GlaxoSmithKline receives Internal Revenue Service notice of deficiency for $1.9 bil. in taxes for years 1997-2000. "GSK disagrees with this tax claim, and the company believes that it has paid all the taxes owed to the U.S. government for these years," GSK said. The company received a separate notice of deficiency in 2004 for $2.7 bil. in taxes for 1989-1996 (1"The Pink Sheet" Jan. 12, 2004, p. 40). The claims are related to allocation of taxes on profits for heritage company Glaxo Wellcome products, GSK says. The company will ask U.S. tax court to consolidate 1997-2000 claim with case pending for the 1989-1996 tax years; a provisional trial date is set for October 2006. GSK estimates interest owed on the two claims would total $3.2 bil. net of federal tax relief if IRS is successful...